The full force of elective procedure shutdowns blasted away at the Total Joints Market in Q220, but Knees took the biggest hit as a higher percentage of knee replacements are considered elective.

As a result of COVID-19, elective procedure shutdowns in early Q220 blasted away at revenue results for the US Total Joints Market. When the dust settled, the US Market for Hips and Knees was down -41.9% according to SmartTRAK Financial Dashboard. US Knees experienced the biggest hit due to its exposure from a higher percentage of elective procedures compared to Hips. US Hips did not come through unscathed but suffered less damage.

Among the many topics covered in the comprehensive Q220 Total Joints Market Recap* are:

Ascension and HOPCo partner together to develop a creative musculoskeletal care platform that could expand across the US

The shift to value-based care in orthopedics has fueled the ongoing debate about the appropriate site-of-care for musculoskeletal conditions – ambulatory surgery center (ASC) vs hospital. However, Ascension Florida and Gulf Coast (Ascension), a part of one of the US’ leading non-profit and Catholic health systems, has a broader more inclusive vision to expand musculoskeletal care in their Florida and Gulf Coast area at the highest possible quality.

Ascension’s vision led them to join forces with the Healthcare Outcomes Performance Company (HOPCo), a company that facilitates the shift to value-based musculoskeletal care, and with Southeast Orthopedic Specialists (Southeast), the largest independent orthopedic practice in the Jacksonville area. In July, Ascension and HOPCo signed an agreement to create and develop a continuum-of-care musculoskeletal platform.

While reverse TSA has grown in popularity, is it always the best option?

Reverse total shoulder arthroplasty (RTSA) was a hot topic during the Current Concepts in Joint Replacement (CCJR) Spring 2020 meeting, held virtually due to the COVID-19 pandemic. Several Orthopaedic Crossfire discussions revolved around RTSA, and surgeons debated several issues, including whether RTSA should be the standard of care for glenohumeral arthritis. The reverse shoulder market segment comprised 54.6% of US Shoulder Market revenue in 2019, compared to 37.1% for anatomic shoulders, according to SmartTRAK estimates.

The Extremities Market was on track to post a strong Q120 finish but due to COVID-19 the market pulled up short

The Extremities Market was in position to post a strong finish in Q120, driven by gains in the US. But the market pulled up short due to the postponement of elective and non-urgent procedures resulting in the US Extremities Market, declining -1.9%, according to SmartTRAK Financial Dashboard.

Among the many topics covered in the comprehensive Q120 Extremities Market Recap* are:

COVID-19 pandemic hit the brakes mid-March resulting in a quick growth slow-down

Q120 was looking like a strong first quarter following Q420’s 4.5% YoY growth, the highest rate seen in the US Total Joints Market for several years. But, the COVID-19 pandemic and the institution of stay-at-home orders in most US states put the brakes on elective procedures in March, resulting in -4.8%, according to SmartTRAK Financial Dashboard. The postponement of procedures and the resulting downturn in revenue late in Q120 also resulted in orthopedic companies withdrawing guidance due to uncertainty about the timing of recovery.

Among the many topics covered in the comprehensive Q120 US Total Joints Market Recap* are:

New research shows excellent results for anatomic TSA using a stemless humeral component with an inlay glenoid. Dr. Gregory Nicholson gives the breakdown on the research, indications, market acceptance and limitations. 

In the market for total shoulder arthroplasty (TSA), younger, active patients with degenerative conditions of the glenohumeral joint are a unique and more complicated population for surgeons to treat with TSA. Challenges in treating this cohort include higher functional demands that can lead to implant wear and failure. However, a recent study suggests a new implant design might be a good option these types of patients, potentially filling a treatment gap and expanding the market for TSA.

Healthy competition ignited by new product intros propels extremities arthroplasty while fixation runs into tough comps along with a lack of new product drivers

Product Mix Shift and Improved Pricing Strengthens US Total Joints Market

In the US, revenue in the Total Joints market for Q419 achieved much stronger growth compared to Q418, according to SmartTRAK Financial Dashboard. Both Hip and Knee Replacement market segments saw growth acceleration. Keep in mind that this growth does not include revenue generated by the sale of robotic systems and associated disposables. The Total Joints market is typically seasonal with a dip in sales during Q3 with recovery in Q4. However, Q419’s uptick seemed particularly strong benefiting from mix shift in products, including the increasing popularity of cementless knees and dual mobility hips.

Among the many topics covered in the comprehensive Q419 US Total Joints Market Recap* are:

The Orthopedic Market experienced healthy growth in H219 fueled by a strong Q319 in the face of difficult comps with the usual fourth-quarter bump due to the seasonality of elective procedures. Looking ahead, several key issues have the potential to impact the US market in 2020. From the economy to taxes, SmartTRAK takes a look at some of the bigger picture issues...

The US Total Joints Market grew +3.4% in Q319, according to SmartTRAK Financial Dashboard, a sequential improvement over Q2’s 1.8% growth. While the extra selling day in the quarter boosted revenue for most Companies, slightly improved pricing and new product introductions also contributed. Wells Fargo’s Larry Biegelsen estimated recon pricing – based on Stryker, Zimmer Biomet, JNJ/DePuy Synthes, and Smith & Nephew– improved to -1.8% YoY. This sequential improvement in growth and pricing is encouraging especially in the face of a difficult comp from Q318 ...

Among the many topics covered in the complete, comprehensive Q319 Total Joints Market Recap* are: